CN102282126A - 多晶型物 - Google Patents

多晶型物 Download PDF

Info

Publication number
CN102282126A
CN102282126A CN2009801549189A CN200980154918A CN102282126A CN 102282126 A CN102282126 A CN 102282126A CN 2009801549189 A CN2009801549189 A CN 2009801549189A CN 200980154918 A CN200980154918 A CN 200980154918A CN 102282126 A CN102282126 A CN 102282126A
Authority
CN
China
Prior art keywords
vorinostat
crystalline
mixture
pharmaceutical composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801549189A
Other languages
English (en)
Chinese (zh)
Inventor
维纳亚克·戈雷
马杜卡尔·帕蒂尔
拉胡尔·巴勒拉奥
赫曼特·曼德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN102282126A publication Critical patent/CN102282126A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801549189A 2008-11-26 2009-11-25 多晶型物 Pending CN102282126A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2057KO2008 2008-11-26
IN2057/KOL/2008 2008-11-26
PCT/GB2009/051596 WO2010061219A2 (en) 2008-11-26 2009-11-25 Polymorphs

Publications (1)

Publication Number Publication Date
CN102282126A true CN102282126A (zh) 2011-12-14

Family

ID=42226168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801549189A Pending CN102282126A (zh) 2008-11-26 2009-11-25 多晶型物

Country Status (8)

Country Link
US (1) US8754129B2 (enExample)
EP (1) EP2362869A2 (enExample)
JP (1) JP2012509929A (enExample)
CN (1) CN102282126A (enExample)
AU (1) AU2009321384A1 (enExample)
CA (1) CA2744448A1 (enExample)
NZ (1) NZ593585A (enExample)
WO (1) WO2010061219A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110283102A (zh) * 2019-05-31 2019-09-27 宿州亿帆药业有限公司 一种伏林司他ⅰ晶型的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080223A (zh) * 2005-05-20 2007-11-28 默克公司 辛二酰苯胺异羟肟酸制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6497820B1 (en) 1998-02-03 2002-12-24 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
CA2663569A1 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
CA2663614A1 (en) 2006-09-28 2008-04-10 Merck And Co., Inc. Amine base salts of saha and polymorphs thereof
AU2008337304A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited HPLC method for analysing clopidogrel
JP2011511053A (ja) 2008-02-07 2011-04-07 ジェネリクス・（ユーケー）・リミテッド ボリノスタットの新規な製造方法
US20090223286A1 (en) 2008-02-13 2009-09-10 Vandana Singh Analytical method for determination of related substances of imipenem and cilastatin
CZ2008167A3 (cs) 2008-03-14 2010-02-24 Zentiva, A. S. Specifické necistoty montelukastu
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat
CA2744458A1 (en) 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
WO2011061545A1 (en) 2009-11-23 2011-05-26 Generics [Uk] Limited Hplc method for analyzing vorinostat

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080223A (zh) * 2005-05-20 2007-11-28 默克公司 辛二酰苯胺异羟肟酸制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHN C. STOWELL ET AL.: "The Synthesis of N-Hydroxy-N"-phenyloctanediamide and Its Inhibitory Effect on Proliferation of AXC Rat Prostate Cancer Cells", 《J. MED. CHEM.》 *
LALJI K. GEDIYA ET AL.: "A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or in Combination with Retinoids on Proliferation of Human Prostate Cancer Cells", 《J. MED. CHEM.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110283102A (zh) * 2019-05-31 2019-09-27 宿州亿帆药业有限公司 一种伏林司他ⅰ晶型的制备方法
CN110283102B (zh) * 2019-05-31 2022-09-27 宿州亿帆药业有限公司 一种伏林司他ⅰ晶型的制备方法

Also Published As

Publication number Publication date
JP2012509929A (ja) 2012-04-26
NZ593585A (en) 2012-12-21
US8754129B2 (en) 2014-06-17
US20110263713A1 (en) 2011-10-27
WO2010061219A2 (en) 2010-06-03
EP2362869A2 (en) 2011-09-07
CA2744448A1 (en) 2010-06-03
WO2010061219A3 (en) 2010-08-12
AU2009321384A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
JP2022531969A (ja) 癌を治療するためのＲａｆ阻害剤としてのＮ－（３－（２－（２－ヒドロキシエトキシ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－２－（トリフルオロメチル）イソニコチンアミドの新規な結晶形態
CA3035124C (en) POLYMORPHIC FORM OF A KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, CONTAINER, PROCESS OF PREPARATION AND USE
CN103974949A (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN103833626B (zh) 西达本胺的晶型及其制备方法与应用
JP6779972B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
CN112142679A (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
WO2014059702A1 (zh) 苯磷硫胺多晶型体、制备方法及其应用
CN102007104A (zh) 4-苯胺喹唑啉衍生物多晶型物及其制法和应用
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
TWI705962B (zh) 喹唑啉衍生物之鹽或其結晶及彼等之製造方法
RU2719484C2 (ru) Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма
US20110269838A1 (en) Novel processes and pure polymorphs
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
WO2025145959A1 (zh) 噻吩嘧啶类化合物的晶型及其制备方法
US8754129B2 (en) Crystalline vorinostat form VI
CN101921227B (zh) 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
CN105461721B (zh) 一种二肽基肽酶-4抑制剂的晶体
CN113801021A (zh) 绿原酸钠水合物及其应用
CN105985252B (zh) 一种门冬氨酸鸟氨酸晶型iv及其制备方法
CN102093387B (zh) 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
CN121270414A (zh) 一种美洛加巴林-4-羟基苯甲酸晶型
CN108117570A (zh) 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN116143709A (zh) 丹酚酸a衍生物的新晶型及其制备方法
TW202506685A (zh) 巨環化合物與其鹽之固體形式及其調配物與製備及使用彼之方法
CN121930164A (zh) 一种乌利沙卡他胺新晶型及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111214